AI是大势。国内和国外都在做，大家都寄希望弯道超车……但是从人资层级结构的重视度上，还是老外这些MNC。真的打算做什么，就新造一些c某o。正好昨天晚上唠嗑了一个国内的AI项目……今天看新闻，就有点唏嘘……
以下新闻来自ciodive
Eli Lilly is taking AI’s potential seriously, announcing Tuesday the appointment of the Indianapolis drugmaker’s first chief AI officer.
礼来公司（Eli Lilly）正在认真对待人工智能的潜力，周二宣布任命这家印第安纳波利斯制药商的首位首席AI官。
Thomas Fuchs, until now the dean and department chair for AI and human health at Mount Sinai, will start in the role on Oct. 21, Lilly said. He will be tasked with setting the “strategic direction” for AI initiatives across Lilly, from the technology’s use in drug discovery to its use in clinical trials and manufacturing.
礼来申明，迄今为止担任西奈山人工智能和人类健康院长兼系主任的 Thomas Fuchs 将于 10 月 21 日开始担任该职务。他的任务是为礼来的人工智能计划设定“战略方向”，从该技术在药物发现中的使用到在临床试验和制造中的使用。
“In this new era of technology, the potential for artificial intelligence and machine learning to revolutionize health care is immense,” Diogo Rau, Lilly’s chief information and digital officer, said in the company’s statement.
“在这个新的技术时代，人工智能和机器学习彻底改变医疗保健的潜力是巨大的，”礼来首席信息和数字化官 Diogo Rau 在公司的声明中说。
The announcement comes the same week as scientists working on AI models won Nobel Prizes in chemistry and in physics, achievements that showcase the field’s rapid advances as well as its applications to scientific problems like how proteins fold into 3D structures.
在宣布这一消息的同一周，从事人工智能模型的科学家获得了诺贝尔化学和物理学奖，这些成就展示了该领域的快速发展及其在科学问题上的应用，例如蛋白质如何折叠成 3D 结构。
At Mount Sinai, Fuchs worked to create AI tools that could help improve patient diagnosis and treatment, as well as make healthcare administration more efficient.
在Mount Sinai，Fuchs 致力于创建有助于改善患者诊断和治疗的 AI 工具，并提高医疗保健管理的效率。
Prior to to his time Mount Sinai, Fuchs worked at Memorial Sloan Kettering Cancer Center, NASA’s Jet Propulsion Laboratory and the California Institute of Technology. He’s founded three companies, including Paige AI, a company that developed AI models for use in cancer pathology and diagnosis.
在加入Mount Sinai之前，Fuchs 曾在纪念斯隆凯特琳癌症中心、NASA 的喷气推进实验室和加州理工学院工作。他创立了三家公司，包括 Paige AI，这是一家开发用于癌症病理学和诊断的 AI 模型的公司。
“The focus of my career was always to develop and build machine learning systems to improve human health and patient care,” Fuchs wrote in a LinkedIn post on his appointment. “I am also convinced that we are just seeing the early beginnings of what AI can do in drug development and in healthcare.”
“我职业生涯的重点一直是开发和构建机器学习系统，以改善人类健康和患者护理，”Fuchs 在关于他任命的 LinkedIn 帖子中写道。“我也相信，我们才刚刚看到 AI 在药物开发和医疗保健领域的作用的早期开始。”
Other pharmaceutical companies are reaching similar conclusions. Earlier this year, Pfizer appointed a former Stellantis and Nvidia executive as its chief AI and analytics officer. Companies like Merck KGaA and GSK have executives in similar roles.
其他制药公司也得出了类似的结论。今年早些时候，辉瑞任命了一位前 Stellantis 和 Nvidia 高管为其首席人工智能和分析官。默克公司 （Merck KGaA） 和葛兰素史克 （GSK） 等公司都有担任类似角色的高管。
Typically in pharma, such positions are nested underneath the chief information or chief digital officer, a role that larger drugmakers only began to add to their executive committees within the past decade.
通常在制药公司，此类职位嵌套在首席信息或首席数字官之下，大型制药商在过去十年中才开始在其执行委员会中增加这一角色。
Even as AI models improve rapidly, their usefulness in drug development has been met with some skepticism given the limits of existing data for training them, and the at-times hazy understanding scientists have of how certain diseases develop.
尽管 AI 模型迅速改进，但鉴于现有训练数据的限制，以及科学家有时对某些疾病如何发展的模糊理解，它们在药物开发中的有用性也遭到了一些怀疑。
